Johns Hopkins HIV Guide
Letermovir
INDICATIONS
FDA
FDA
- Prophlyaxis of cytomegalovirus infection (CMV) in patients (> 18 years of age) who are CMV-seropositive and have undergone an allogeneic stem cell transplant
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: June 6, 2018
Citation
Dzintars, Kathryn. "Letermovir." Johns Hopkins HIV Guide, 2018. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir.
Dzintars K. Letermovir. Johns Hopkins HIV Guide. 2018. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir. Accessed September 28, 2023.
Dzintars, K. (2018). Letermovir. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir
Dzintars K. Letermovir [Internet]. In: Johns Hopkins HIV Guide. ; 2018. [cited 2023 September 28]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Letermovir
ID - 545271
A1 - Dzintars,Kathryn,Pharm.D., BCPS
Y1 - 2018/06/06/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545271/all/Letermovir
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
